alfa1 antitrypsinbrist - dofaq.co
Health-related QoL in Alpha-1 Antitrypsin Deficiency-Associated COPD - COPD: Peer Perspectives
Medpage Today - 15 Apr 2024
Health-related QoL in Alpha-1 Antitrypsin Deficiency-Associated COPD - COPD: Peer Perspectives ...
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of ...
Yahoo Finance - 26 Mar 2024
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of ... ...
Alpha-1 Antitrypsin Deficiency Market to Register Incremental Growth by 2032, Assesses DelveInsight | Key ...
PR Newswire - 18 Jan 2024
Alpha-1 Antitrypsin Deficiency Market to Register Incremental Growth by 2032, Assesses DelveInsight | Key ... ...
Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin ...
GlobeNewswire - 23 Jan 2024
Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin ... ...
Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Trends Suggest A USD 2517 Million Valuat
PharmiWeb.com - 18 Apr 2024
Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Trends Suggest A USD 2517 Million Valuat ...
Infographic: Alpha 1 Fast Facts
CSL Limited - 01 Nov 2023
Infographic: Alpha 1 Fast Facts ...
Alpha-1 antitrypsin protects against phosgene-induced acute lung injury by activating the ID1-dependent anti ...
ScienceDirect.com - 15 Oct 2023
Alpha-1 antitrypsin protects against phosgene-induced acute lung injury by activating the ID1-dependent anti ... ...
Vertex drops phase 2 lung therapy, rethinks DMD drug's journey toward clinic
Fierce Biotech - 07 Nov 2023
Vertex drops phase 2 lung therapy, rethinks DMD drug's journey toward clinic ...
Study shows survival benefit of augmentation therapy for people with the genetic lung condition AATD
Medical Xpress - 01 Nov 2023
Study shows survival benefit of augmentation therapy for people with the genetic lung condition AATD ...
UK clearance for phase I/II trial of Beam's BEAM-302 for α1-antitrypsin deficiency
BioWorld Online - 27 Mar 2024
UK clearance for phase I/II trial of Beam's BEAM-302 for α1-antitrypsin deficiency ...
CSL Behring Demonstrates Continued Commitment to Alpha-1 Community with Addition of ZEMAIRA® [Alpha1 ...
PR Newswire - 02 Jan 2024
CSL Behring Demonstrates Continued Commitment to Alpha-1 Community with Addition of ZEMAIRA® [Alpha1 ... ...
Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA ...
GlobeNewswire - 06 Dec 2023
Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA ... ...
Increased expression or activation of TRPML1 reduces hepatic storage of toxic Z alpha-1 antitrypsin
ScienceDirect.com - 06 Sep 2023
Increased expression or activation of TRPML1 reduces hepatic storage of toxic Z alpha-1 antitrypsin ...
Alpha 1 Antitrypsin Deficiency Facts & Resources
CSL Limited - 01 Jun 2023
Alpha 1 Antitrypsin Deficiency Facts & Resources ...
Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States ...
PR Newswire - 19 Sep 2023
Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States ... ...
Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT ...
GlobeNewswire - 07 Sep 2023
Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT ... ...
Testing Patterns and Disparities for Alpha-1 Antitrypsin Deficiency
ScienceDirect.com - 13 Jul 2023
Testing Patterns and Disparities for Alpha-1 Antitrypsin Deficiency ...
Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency
PR Newswire - 30 May 2023
Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency ...
Takeda Enters Into Two-Year Contract with Canadian Blood Services for GLASSIA®, Treatment for Rare form of ...
Yahoo Finance - 20 Dec 2023
Takeda Enters Into Two-Year Contract with Canadian Blood Services for GLASSIA®, Treatment for Rare form of ... ...